en
/
fr
Ethics Portal
Who We Are
Vision & Mission
Our Model
Strategy
Governance & Team
Governance Board
Expert Advisory Group
MPP Staff (A to Z)
Ethics Portal
Funding
Who We Work With
What We Do
Our Work
HIV
Hepatitis C
Tuberculosis
Paediatrics
Licence Overview
Products Licensed
Key features of MPP licences
Update on Progress
Other Partnerships
Expression of Interest
Projections
Projections Tool
Target Medicines
Media
Endorsements
Press
Press Kit
Press Releases
Statements
Highlights
Features
Message from the Executive Director
‘First Person’ series
Dolutegravir – making a difference to people’s lives
MPP in the News
Events
Resources
MedsPaL
Q&A on MedsPaL
Publications
Annual Reports
MPP Publications
Related Publications
Projections
Multimedia
Newsletters
Glossary
Documents
Resources Search
Contact
Resources Search
Newsletter
26 June 2012
June 2012 Newsletter
Newsletter
26 April 2012
April 2012 Newsletter
Newsletter
13 February 2012
February 2012 Newsletter
Newsletter
23 December 2011
December 2011 Newsletter
Annual Reports
01 December 2011
Annual Report 2010-2011 – First annual report
Newsletter
17 November 2011
November 2011 Newsletter
Newsletter
14 September 2011
September 2011 Newsletter
Related Publication
01 September 2011
UNAIDS: Doha+10: TRIPS Flexibilities and Access to Antiretroviral Therapy: Lessons from the past, opportunities for the future
Newsletter
12 July 2011
July 2011 Newsletter
Newsletter
08 June 2011
June 2011 Newsletter
Newsletter
11 May 2011
May 2011 Newsletter
MPP Publications
01 April 2011
MPP: Comments to the US Patent and Trademark Office
« Previous
1
…
10
11
12
13
Next »
Keywords
Resource Type
All
Annual Reports
Document
MPP Publications
Newsletter
Projections
Publication
Related Publication
Disease
All
Hepatitis C
HIV
TB
Search
Cookie Policy
This website uses cookies to ensure you get the best experience on our website.
Learn More
Decline
Allow Cookies